ALVR
Allovir
–
Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 2.03B; Volume: 955.91K; AvgVol 3m: 588.82K; Beta: –;
Cost estimate:
P/E: –; EPS: -0.44; EPS growth quarter/prev quarter: ;
EPS growth this year: -192.30%; EPS growth past 5 years: ;
EPS ttm: -0.44;
P/S: ; P/B: ; P/Cashflow: 16.82; P/FCF: ;
Sales: 170.00K; Sales growth quarter/prev quarter: ; Sales growth past 5 years: ;
Profitability:
Gross Margin: ; Profit Margin: ; Operating Margin: ;
ROA – return on assets: ; ROE – return on equity: ; LT Debt/Equity: ; Total Debt/Equity: ;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 36.40%; Insider Transactions:14.17%;
Institutional Ownership: ; Institutional Transactions: ;
Data update: 07.10.2020.